Literature DB >> 29274830

The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids.

Sukhbir S Singh1, Liane Belland2, Nicholas Leyland3, Sarah von Riedemann4, Ally Murji5.   

Abstract

Uterine fibroids are common in women of reproductive age and can have a significant impact on quality of life and fertility. Although a number of international obstetrics/gynecology societies have issued evidence-based clinical practice guidelines for the management of symptomatic uterine fibroids, many of these guidelines do not yet reflect the most recent clinical evidence and approved indication for one of the key medical management options: the selective progesterone receptor modulator class. This article aims to share the clinical experience gained with selective progesterone receptor modulators in Europe and Canada by reviewing the historical development of selective progesterone receptor modulators, current best practices for selective progesterone receptor modulator use based on available data, and potential future uses for selective progesterone receptor modulators in uterine fibroids and other gynecologic conditions.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  leiomyomas; selective progesterone receptor modulators; ulipristal acetate; uterine fibroids; women’s health

Mesh:

Substances:

Year:  2017        PMID: 29274830     DOI: 10.1016/j.ajog.2017.12.206

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

Review 1.  Importance of Fibrosis in the Pathogenesis of Uterine Leiomyoma and the Promising Anti-fibrotic Effects of Dipeptidyl Peptidase-4 and Fibroblast Activation Protein Inhibitors in the Treatment of Uterine Leiomyoma.

Authors:  Anusha Shreenidhi Bhat; Ningthoujam Anirudh Singh; Emdormi Rymbai; Swapna Birendra; Saravanan Jayaram; Divakar Selvaraj
Journal:  Reprod Sci       Date:  2022-08-15       Impact factor: 2.924

2.  Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.

Authors:  Thomas E Bartlett; Iona Evans; Allison Jones; James E Barrett; Shaun Haran; Daniel Reisel; Kiriaki Papaikonomou; Louise Jones; Chiara Herzog; Nora Pashayan; Bruno M Simões; Robert B Clarke; D Gareth Evans; Talayeh S Ghezelayagh; Sakthivignesh Ponandai-Srinivasan; Nageswara R Boggavarapu; Parameswaran G Lalitkumar; Sacha J Howell; Rosa Ana Risques; Angelique Flöter Rådestad; Louis Dubeau; Kristina Gemzell-Danielsson; Martin Widschwendter
Journal:  Genome Med       Date:  2022-06-15       Impact factor: 15.266

3.  Uterine fibroids and risk of hypertension: Implication of inflammation and a possible role of the renin-angiotensin-aldosterone system.

Authors:  Decio Armanini; Chiara Sabbadin; Gabriella Donà; Luciana Bordin; Loris Marin; Alessandra Andrisani; Guido Ambrosini
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-03-22       Impact factor: 3.738

Review 4.  Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids.

Authors:  Mei-An Middelkoop; Maria E de Lange; T Justin Clark; Ben Willem J Mol; Pierre M Bet; Judith A F Huirne; Wouter J K Hehenkamp
Journal:  Hum Reprod       Date:  2022-05-03       Impact factor: 6.353

Review 5.  The Role of Tumor Necrosis Factor α in the Biology of Uterine Fibroids and the Related Symptoms.

Authors:  Michał Ciebiera; Marta Włodarczyk; Magdalena Zgliczyńska; Krzysztof Łukaszuk; Błażej Męczekalski; Christopher Kobierzycki; Tomasz Łoziński; Grzegorz Jakiel
Journal:  Int J Mol Sci       Date:  2018-12-04       Impact factor: 5.923

6.  Meta-Study of the Clinical Effect of Conservative Treatment in Uterine Fibroids.

Authors:  Hanxiao Zhu; Xiaoli Lai; Jinhong Wu; Chenan Guan; Junhui Yu
Journal:  J Oncol       Date:  2022-07-31       Impact factor: 4.501

Review 7.  Aldosterone in Gynecology and Its Involvement on the Risk of Hypertension in Pregnancy.

Authors:  Chiara Sabbadin; Alessandra Andrisani; Guido Ambrosini; Luciana Bordin; Gabriella Donà; Jacopo Manso; Filippo Ceccato; Carla Scaroni; Decio Armanini
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-23       Impact factor: 5.555

8.  Ulipristal acetate for Japanese women with symptomatic uterine fibroids: A double-blind, randomized, phase II dose-finding study.

Authors:  Minoru Irahara; Yasuhiro Maejima; Nobuhiro Shinbo; Yuji Yamauchi; Hideki Mizunuma
Journal:  Reprod Med Biol       Date:  2019-10-30

9.  Asoprisnil, a Selective Progesterone Receptor Modulator (SPRM), Inhibits Melanosome Export in B16F10 Cells and HEMn-DP Melanocytes.

Authors:  Shilpi Goenka; Sanford R Simon
Journal:  Molecules       Date:  2020-08-06       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.